Skip to main content
SpringerLink
Log in

Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis

  • Review Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Treatment of Parkinson’s disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and safety of LCE in the treatment of early Parkinson’s disease (PD) still need to be assessed. Our objective was to do a meta-analysis of relevant randomized controlled trials (RCTs) to evaluate the efficacy and safety of LCE for early PD. PubMed, Embase, the Cochrane Library, and the Web of Science were searched for RCTs with “levodopa/carbidopa/entacapone” and “Parkinson’s disease” as keywords. The search period was from inception to October 2018. The quality of included studies was strictly evaluated. We evaluated the quality of included studies strictly and six studies met all inclusion criteria. The results showed that LCE could improve activities of daily living and motor function in PD patients. However, LCE therapy was associated with higher risks of total AEs and single AEs compared with traditional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hirsch EC, Jenner P, Przedborski S (2013) Pathogenesis of Parkinson’s disease. Mov Disord 28(1):24–30. https://doi.org/10.1002/mds.25032

    Article  CAS  PubMed  Google Scholar 

  2. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912. https://doi.org/10.1016/s0140-6736(14)61393-3

    Article  CAS  PubMed  Google Scholar 

  3. Chen Y, Shen J, Ke K, Gu X (2020) Clinical potential and current progress of mesenchymal stem cells for Parkinson’s disease: a systematic review. Neurol Sci 1:11. https://doi.org/10.1007/s10072-020-04240-9

    Article  Google Scholar 

  4. Gaenslen A, Berg D (2010) Early diagnosis of Parkinson’s disease. Int Rev Neurobiol 90:81–92. https://doi.org/10.1016/s0074-7742(10)90006-8

    Article  PubMed  Google Scholar 

  5. Ossig C, Reichmann H (2015) Treatment strategies in early and advanced Parkinson disease. Neurol Clin 33(1):19–37. https://doi.org/10.1016/j.ncl.2014.09.009

    Article  PubMed  Google Scholar 

  6. Brooks DJ (2008) Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 4(1):39–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism—chronic treatment with L-dopa. N Engl J Med 280:337–345

    Article  CAS  PubMed  Google Scholar 

  8. Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/s1474-4422(16)30230-7

    Article  PubMed  Google Scholar 

  9. Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone—a review. J Neural Transm (Vienna) 111(10–11):1343–1363. https://doi.org/10.1007/s00702-004-0190-3

    Article  CAS  Google Scholar 

  10. Fung VSC, Herawati L, Wan Y, Boyle R, Hughes A, Lueck C et al (2009) Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. Mov Disord 24(1):25–31. https://doi.org/10.1002/mds.21878

    Article  PubMed  Google Scholar 

  11. Poulopoulos M, Waters C (2010) Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease. Core Evid 5:1–10

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Tveiten OV, Skeie GO, Haugarvoll K, Muller B, Larsen JP, Tysnes OB (2013) Treatment in early Parkinson’s disease: the Norwegian ParkWest study. Acta Neurol Scand 128(2):107–113. https://doi.org/10.1111/ane.12055

    Article  CAS  PubMed  Google Scholar 

  13. Espay AJ, Pagan FL et al (2017) Optimizing extended-release carbidopa/levodopa in Parkinson disease: consensus on conversion from standard therapy. Neurol Clin Pract 7:86–93

    Article  PubMed  PubMed Central  Google Scholar 

  14. Abbruzzese G (2008) Optimising levodopa therapy. Neurol Sci 29:377–379. https://doi.org/10.1007/s10072-008-1051-x

    Article  Google Scholar 

  15. Zambito Marsala S, Vitaliani R, Volpe D, Capozzoli F, Baroni L, Belgrado E, Borsato C, Gioulis M, Marchini C, Antonini A (2013) Rapid onset of efficacy of rasagiline in early Parkinson’s disease. Neurol Sci 34:2007–2013. https://doi.org/10.1007/s10072-013-1437-2

    Article  PubMed  Google Scholar 

  16. Getz SJ, Levin B (2017) Cognitive and neuropsychiatric features of early Parkinson’s disease. Arch Clin Neuropsychol 32(7):769–785. https://doi.org/10.1093/arclin/acx091

    Article  PubMed  Google Scholar 

  17. Lew MF, Somogyi M, McCague K, Welsh M (2011) Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson’s disease with end-of-dose wearing off. Int J Neurosci 121(11):605–613. https://doi.org/10.3109/00207454.2011.598982

    Article  CAS  PubMed  Google Scholar 

  18. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, Grp F-SS (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord 24(4):541–550. https://doi.org/10.1002/mds.22343

    Article  PubMed  Google Scholar 

  19. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27. https://doi.org/10.1002/ana.22060

    Article  CAS  PubMed  Google Scholar 

  20. Tolosa E, Hernández B, Linazasoro G, López-Lozano JJ, Mir P, Marey J, Kulisevsky J (2014) Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing early wearing-off: a randomised, double-blind trial. Journal of neural transmission (vienna, austria : 1996) 121(4):357–366. https://doi.org/10.1007/s00702-013-1114-x

    Article  CAS  Google Scholar 

  21. Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A (2005) Treatment of end-of-dose wearing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 53(4):197–202. https://doi.org/10.1159/000086479

    Article  CAS  PubMed  Google Scholar 

  22. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M (2003) The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol 10(2):137–146

    Article  CAS  PubMed  Google Scholar 

  23. Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M (2001) Twelve-month safety of entacapone in patients with Parkinson’s disease. Eur J Neurol 8(1):53–60

    Article  CAS  PubMed  Google Scholar 

  24. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245–255

    Article  CAS  PubMed  Google Scholar 

  25. Kuoppamaki M, Vahteristo M, Ellmen J, Kieburtz K (2014) Pooled analysis of phase III with entacapone in Parkinson’s disease. Acta Neurol Scand 130(4):239–247. https://doi.org/10.1111/ane.12278

    Article  CAS  PubMed  Google Scholar 

  26. Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD (2018) Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag 14:709–719. https://doi.org/10.2147/tcrm.S163190

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Rosendaal FR, Reitsma PH (2014) Meta-analysis. J Thromb Haemost 12(7):1009. https://doi.org/10.1111/jth.12616

    Article  CAS  PubMed  Google Scholar 

  28. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J et al (2011) The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS One 6(10):e25491. https://doi.org/10.1371/journal.pone.0025491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study is supported by the Sichuan Science and Technology Program (No. 18PTDJ0117 and 2018ZDYF0569).

Author information

Author notes

  1. Liao Xiaoli, Wu Nianyue and Liu Dongfeng contributed equally to this work.

Authors and Affiliations

  1. School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China

    Liao Xiaoli, Wu Nianyue, Liu Dongfeng, Shuai Bowei, Li Shilei & Li Ke

Authors
  1. Liao Xiaoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wu Nianyue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liu Dongfeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuai Bowei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Shilei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Liao Xiaoli, Wu Nianyue, and Liu Dongfeng contributed equally. Data for each study were extracted independently by two researchers (Wu and Liu). If there is any ambiguity, consult a third investigator (Liao). Similarly, three researchers made similar contributions to the writing of the manuscript. Wu and Liu completed the preliminary manuscript. Liao is responsible for the final revision.

Corresponding author

Correspondence to Li Ke.

Ethics declarations

Conflict of interest

None.

Ethical approval

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liao, X., Wu, N., Liu, D. et al. Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis. Neurol Sci 41, 2045–2054 (2020). https://doi.org/10.1007/s10072-020-04303-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-020-04303-x

Keywords

Search

Navigation